Recent Finacing
Recent Raise
Elpis Biopharmaceuticals develops multifunctional immunotherapies using mRNADis™ and mSCAFold™ platforms to engineer bispecific antibodies, armored CAR‑T cells, and immunomodulatory proteins targeting tumor resistance via combined targeting and immune activation.